Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Methylparaben. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | CA2 | P00918 | 6/20 | 0.61 |
| ▸ | CA12 | O43570 | 4/20 | 0.61 |
| ▸ | CA9 | Q16790 | 4/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylparaben SCHEMBL48756 | 0.95 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| Methylparaben SCHEMBL2810863 | 0.95 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28993944 | 0.85 | CA1 (0.80) | CA1CA2CA12CA9CA14 | |
| SCHEMBL23600 | 0.85 | CA1 (0.80) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28531063 | 0.83 | CA1 (0.76) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28993277 | 0.83 | CA1 (0.76) | CA1CA2CA12CA9CA14 | |
| Ammonia Solution, Strong SCHEMBL28873355 | 0.83 | CA1 (0.76) | CA1CA2CA12CA9CA14 | |
| Methyl Alcohol SCHEMBL28561085 | 0.83 | CA1 (0.76) | CA1CA2CA12CA9CA14 | |
| Water SCHEMBL22720573 | 0.83 | CA1 (0.76) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28704033 | 0.83 | CA1 (0.76) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724590-A1 | ADENO-ASSOCIATED VIRUS FORMULATIONS | 4D Molecular Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12553062-B2 | AAV compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20250255862-A1 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | AMGEN INC. | 2025-08-14 | — | — | US | disclosed |
| US-12295952-B2 | Methods of treating heart failure with cardiac sarcomere activators | CYTOKINETICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12269900-B2 | Inhibitors of β integrin-G protein α subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-08 | — | — | US | disclosed |
| US-12257277-B2 | Adeno-associated virus formulations | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-03-25 | — | — | US | disclosed |
| EP-4512470-A2 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | Amgen Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250002868-A1 | ADENO-ASSOCIATED VIRUS SEPARATION ON A CATION EXCHANGER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-02 | — | — | US | disclosed |
| WO-2024254052-A1 | ADENO-ASSOCIATED VIRUS FORMULATIONS | 4D MOLECULAR THERAPEUTICS INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-3645002-B1 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | AMGEN INC (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-2300037-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | Indiana University Research and Technology Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2011032099-A1 | METHODS OF TREATING DIASTOLIC DYSFUNCTION AND RELATED CONDITIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010148089-A1 | GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010111617-A2 | PARATHYROID HORMONE PEPTIDES AND PARATHYROID HORMONE-RELATED PROTEIN PEPTIDES AND METHODS OF USE | VAN ANDEL RESEARCH INSTITUTE (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010071807-A1 | AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010011439-A2 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009155258-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155257-A1 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY PHYSIOLOGICAL PH BUFFERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| US-5100773-A | Yellow coupler with good dispersion stability | KONICA CORPORATION (JP) | 1992-03-31 | — | — | US | disclosed |
| EP-0371768-A1 | Silver halide color photographic light-sensitive material | KONICA CORPORATION (JP) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255862-A1 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | TNNC1, TNNT2, TNNI3 | CA1 3658/4885CA2 1212/4885CA12 4496/4885 |
| US-12295952-B2 | Methods of treating heart failure with cardiac sarcomere activators | TNNC1, TNNT2, TNNI3 | CA1 3658/4885CA2 1212/4885CA12 4496/4885 |
| US-12553062-B2 | AAV compositions | PRDM9, H1-10, SLC20A1 | CA1 495/4885CA2 2353/4885CA12 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.